Sanofi, Scribe Therapeutics, and Biogen are partnering on ALS gene therapy research, seeking a second research deal and initial public offering on Nasdaq.
2 reports, 1 independent
Updated Jul 6
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Sanofi, Scribe Therapeutics, and Biogen are partnering on ALS gene therapy research, seeking a second research deal and initial public offering on Nasdaq.